Related Experiment Video
Updated: Aug 19, 2026
Hemodynamic Precision in the Neonatal Intensive Care Unit using Targeted Neonatal Echocardiography
Published on: January 27, 2023
Recombinant human erythropoietin therapy in low-birthweight preterm infants: a prospective controlled study
1Department of Pediatrics, Gulhane Military Medical Academy Haydarpasa Training Hospital, Istanbul, Turkey. Arbahar@Hotmail.com
Insights
Recombinant erythropoietin (EPO) effectively prevents anemia in premature infants, significantly reducing the need for blood transfusions. This therapy helps maintain stable hematocrit levels in these vulnerable newborns.
Area of Science:
- Neonatalogy
- Hematology
- Pharmacology
Background:
- Premature infants, especially those with low birthweight, are at high risk for anemia.
- Anemia in preterm infants can lead to serious complications and necessitate blood transfusions.
Purpose of the Study:
- To evaluate the effectiveness of recombinant human erythropoietin (EPO) in preventing anemia.
- To assess the impact of EPO therapy on hematocrit levels and transfusion requirements in low-birthweight preterm infants.
Main Methods:
- A randomized controlled trial involving 292 preterm infants (gestational age < 33 weeks, birthweight < 1500 g).
- The treatment group (142 infants) received subcutaneous recombinant EPO (200 U/kg twice weekly for 6 weeks) alongside conventional therapy.
- The control group (150 infants) received only conventional supportive therapy.
- Outcomes including blood counts, hematocrit, ferritin levels, and transfusion needs were monitored over 6 months.
Main Results:
- EPO therapy significantly increased serum EPO levels and reticulocyte counts (P < 0.001).
- Hematocrit values were significantly higher in the EPO-treated group compared to the control group (P < 0.001).
- The need for packed red blood cell transfusions was significantly lower in the EPO group (47%) versus the control group (62.6%) (P < 0.001).
- No adverse side-effects related to EPO administration were observed.
Conclusions:
- Recombinant human erythropoietin is a safe and effective treatment for preventing anemia in low-birthweight preterm infants.
- EPO therapy helps maintain stable hematocrit levels and reduces the requirement for blood transfusions in this population.
Background:
This study aimed to detect the effectiveness of recombinant human erythropoietin therapy in preventing premature anemia in low-birthweight preterm infants.
Methods:
A total of 292 premature infants who were born earlier than 33 gestational weeks and smaller than 1500 g birthweight were enrolled into the study. In addition to their conventional supportive therapy (medications), recombinant human erythropoietin 200 U/kg twice a week, subcutaneously, was given to randomly selected 142 premature infants for 6 weeks. The blood count variables and need for transfusions were compared with the remaining 150 premature infants during 6 months follow up.
Results:
Serum erythropoietin levels were 11.3 +/- 6.1 mU/mL and 38.3 +/- 19.1 mU/mL in the erythropoietin group before and at the fourth week of the study, respectively (P < 0.001). Reticulocyte counts of the group treated with erythropoietin were 146 x 10(6) +/- 28 x 10(6)/mL and 122 x 10(6) +/- 27 x 10(6)/mL at the fourth and seventh week of the study, respectively, and these values were significantly higher when compared with the control group (P < 0.001 and P < 0.001). At the same period, hematocrit values were also found to be higher in the treatment group than the control group (P < 0.001). Serum ferritin levels were lower in the treatment group compared with the control group at the fourth week of the study. No side-effects related to erythropoietin usage were encountered. The need for packed cell transfusions were 47% in the group treated with erythropoietin and 62.6% in the control group. A statistically significant difference was found for transfusion needs between the control and treatment groups (P < 0.001).
Conclusion:
Recombinant erythropoietin is effective therapy for maintaining stable hematocrit levels in low-birthweight preterm infants and prevents the need for blood transfusions.
